Ceftobiprole
![]() |
|
Systematic (IUPAC) name | |
---|---|
(6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)- 2-nitroso-1-oxoethyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)- 3-pyrrolidinyl]-3-pyrrolidinylidene]methyl]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Legal status | |
Routes of administration |
Intravenous |
Identifiers | |
CAS Number | 209467-52-7 ![]() Template:CAS (medocaril) |
ATC code | J01DI01 (WHO) [1] |
PubChem | CID: 6918430 |
ChemSpider | 21106277 ![]() |
UNII | 5T97333YZK ![]() |
KEGG | D08885 ![]() |
ChEMBL | CHEMBL520642 ![]() |
Chemical data | |
Formula | C20H22N8O6S2 |
Molecular mass | 534.568 g/mol |
|
|
|
|
![]() ![]() |
Ceftobiprole (Zeftera/Zevtera) is a fifth-generation[2] cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Pseudomonas aeruginosa, and enterococci.[3][4][5] It was discovered by Basilea Pharmaceutica[6] and was developed by Johnson & Johnson Pharmaceutical Research and Development.[7] It has been shown to be statistically noninferior to the combination of vancomycin and ceftazidime for the treatment of skin and soft tissue infections.[8]
It has been described as a fifth-generation cephalosporin,[9][10] though acceptance for this terminology is not universal.
Pharmacology
Like other cephalosporins, ceftobiprole inhibits bacterial growth by blocking penicillin-binding protein, a key enzyme involved in cell wall synthesis. Ceftobiprole inhibits the 2a penicillin-binding protein (PBP) of methicillin-resistant Staphylococcus aureus and the 2x PBP of Streptococcus pneumoniae,[4] as well as the classic PBP-2 of MSSA. Ceftobiprole is resistant to staphylococcal β-lactamase.[6]
Mode of administration
Ceftobiprole is given intravenously; it cannot be given by mouth.
Regulatory approvals
Ceftobiprole has been approved for use in Canada, Switzerland, and the European Union.[11] It is under review by regulatory authorities in the United States, Australia, Russia, and South Africa.[12] In November 2008, the US FDA declined to approve ceftobiprole, citing data integrity concerns with two of the supporting studies,[13] and prompting Basilea to sue Johnson & Johnson for breach of license agreement on February 2009.[14]
Synonyms
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 4.0 4.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 6.0 6.1 6.2 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Basilea.com
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Basilea antibiotic to treat pneumonia wins European backing. Reuters, ZURICH | Wed Oct 23, 2013.
- ↑ Basilea superbug drug approved in Canada, Reuters News, June 30, 2008
- ↑ http://www.dancewithshadows.com/pillscribe/ceftobiprole-antibiotic-to-fight-tougher-bacterial-infections-fails-to-win-approval-in-us/
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.